

## Recombinant Human KDR(C-6His)

Catalog No: CB26

<b>Description</b>	Recombinant Human Vascular endothelial growth factor receptor 2 is produced by our Mammalian expression system and the target gene encoding Ala20-Glu764 is expressed with a 6His tag at the C-terminus.	
<b>Source</b>	Human Cells	
<b>Alternative name</b>	Vascular endothelial growth factor receptor 2; KDR; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1	
<b>Accession No.</b>	P35968	
<b>Predicted Molecular Weight</b>	84.3 kDa	
<b>AP Molecular Weight</b>	84-95 kDa, reducing conditions	
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution of PBS,pH7.4.	
<b>Quality Control</b>	Purity	Greater than 95% as determined by reducing SDS-PAGE.
	Endotoxin	Less than 0.1 ng/µg (1 EU/µg)
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.	
<b>Storage</b>	Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.	
<b>Background</b>	Human Vascular endothelial growth factor receptor 2(KDR, VEGFR-2) is a member of the class III subfamily of receptor tyrosine kinases (RTKs). KDR is involved in a number of fundamental biological processes such as the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. It also plays an essential role in promoting proliferation, survival, migration and differentiation of endothelial cells, reorganization of the actin cytoskeleton. VEGFR2 is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. The adaptor protein SHB has been shown to interact with VEGFR2 in receptor tyrosine kinase signaling. In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.	

### SDS-PAGE

